Collagen Solutions PLC FDA approval for NovaBone product
September 03 2015 - 1:00AM
RNS Non-Regulatory
TIDMCOS
Collagen Solutions PLC
03 September 2015
Collagen Solutions Plc
(the "Company" or the "Group")
FDA approval for NovaBone product
Collagen Solutions plc (AIM: COS), the developer and
manufacturer of medical grade collagen components for use in
regenerative medicine, medical devices and in-vitro diagnostics,
announces that its long term client, NovaBone Products LLC
(NovaBone), has had a novel device approved by the US FDA, for use
in the delivery of its collagen bone graft product MacroFORM.
NovaBone has received FDA approval for the NovaBone MacroFORM
MIS Delivery System designed for minimally invasive orthopedic
procedures. The system was developed for surgeons requiring
controlled and precise delivery of collagen bone grafting material
to surgical sites that aren't readily accessible. NovaBone's
MacroFORM technology allows the delivery of bone marrow aspirate
and other bioactive formulations to a graft in a ready to use,
minimally invasive cannula.
NovaBone has introduced six new collagen products in the last 12
months for use in the wound care and bone graft markets based on
the Company's novel regenerative medicine technology and core
competencies in designing innovative and cost-effective medical
devices. These products use medical grade collagen supplied by
Collagen Solutions plc.
Commenting on the approval Stewart White, CEO of Collagen
Solutions, said: "Once again, we see the long-term value generation
that we can gain by having our collagen embedded into novel
products. This impressive innovation by the team at NovaBone around
making their collagen products easier to use ensures a commitment
to growth of these products within attractive addressable markets.
It is anticipated this regulatory approval for NovaBone will have a
direct effect on revenues to Collagen Solutions."
Art Wotiz, President of NovaBone Products said "We continue to
reach milestones we have established. Our team has done an
excellent job in terms of both design and manufacturing of collagen
products and creating a robust pipeline of products that harness
the natural healing process of the body."
Enquiries:
Collagen Solutions Plc
David Evans, Chairman Tel: 07740 084 452
Stewart White, CEO Tel: 0141 648 9100
Panmure Gordon & Co (Nominated Tel: 0207 8862 714
Advisor and Broker) Tel: 020 7886 2905
Robert Naylor (Corporate Finance)
Maisie Atkinson (Corporate Broking)
Walbrook PR Ltd Tel: 0207 9338 780 or
collagen@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Mike Wort Mob: 07900 608 002
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAENAELFSEAF
(END) Dow Jones Newswires
September 03, 2015 02:00 ET (06:00 GMT)
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Jul 2023 to Jul 2024